Vertex Pharmaceuticals Price to Book Ratio

Vertex Pharmaceuticals (VRTX) currently reports a P/B ratio of 6.37. That is above the Healthcare sector average of 6.17. Use the charts on this page to explore Vertex Pharmaceuticals's P/B ratio history and peer comparisons.

Vertex Pharmaceuticals's P/B ratio of 6.37 is higher than the Healthcare sector average of 6.17. That is roughly 3.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/B ratio is a valuation multiple that relates Vertex Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 6.37, VRTX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/B ratio of 6.37, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 6.17. From there, open related valuation or income-statement pages for Vertex Pharmaceuticals, and consider following VRTX for alerts when major investors trade the stock.

Vertex Pharmaceuticals is classified in the Healthcare sector. On P/B ratio, it currently shows 6.37 versus a sector average near 6.17. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VRTX with unrelated industries.